首页> 外文OA文献 >Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

【2h】

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

机译：从一系列FDA批准的药物中鉴定出新型抗胶质母细胞瘤药物和治疗组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Pengfei Jiang; Rajesh Mukthavavam; Ying Chao; Ila Bharati; Valentina Fogal; Sandra Pastorino; Xiuli Cong; Natsuko Nomura; Matt Gallagher; Taher Abbasi; Shireen Vali; Sandeep C Pingle; Milan Makale; Santosh Kesari;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Actions Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第9期

机译：当前与FDA有关的药物信息由FDA批准的新药物新剂型和适应症，由FDA代理商批准的待批FDA批准的新药/生物许可申请，由制造商提出的补充措施，由制造商提出的重要措施，或与“亲爱的健康专业人员”的信件有关安全
2. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第8期

机译：当前与FDA有关的药物信息由FDA批准的新药物，由FDA代理批准的新剂型和适应症，待FDA批准的新药物/生物学许可由制造商提交的重要标签变更或与安全相关的“亲爱的健康专业人员”信函
3. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2010,第6期

机译：当前与FDA有关的药物信息由FDA批准的新药物，由FDA代理商批准的新剂型和适应症，待FDA批准的制造商提出的新药/生物许可申请，制造商提出的补充申请，重要的标签变更或与“亲爱的健康专业人员”的信件安全
4. UHPLC-HRMS Method for Repurposing FDA Approved Drugs: Primaquine and its Metabolites as Anticancer Therapeutics [C] . Samantha M. Mahmoud, Dil Ramanathan American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：用于修复FDA批准的药物的UHPLC-HRMS方法：原序及其代谢产物作为抗癌治疗方法
5. Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study [D] . Alqahtani, Saad. 2017

机译：FDA批准的药物与蛋白质结合的分子决定因素–数据挖掘和先进的量子化学研究
6. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs [O] . Pengfei Jiang, Rajesh Mukthavavam, Ying Chao, 2014

机译：从一系列FDA批准的药物中鉴定出新型抗胶质母细胞瘤药物和治疗组合
7. Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs [O] . Pengfei Jiang, Rajesh Mukthavaram, Ying Chao, 2014

机译：更正：从FDA批准的药物中鉴定出的新型抗胶质母细胞瘤药物和治疗组合
8. Guidance for FDA Staff and Industry: Marketed Unapproved Drugs. Compliance Policy Guide. Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs (September 19, 2011) [R] . 2011

机译：FDa工作人员和行业指南：未经批准的未经批准的药物。合规政策指南。秒。 440.100未经批准的NDa或aNDa上市的新药（2011年9月19日）

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

著录项

引文网络

相似文献

相关主题

期刊订阅